

Curriculum vitae

Giovanni Blandino

Regina Elena National Cancer Institute

Rome, Italy

December 2012

Dr. Giovanni Blandino, M.D., M.Sc.

Personal Information

Place of Birth: Scicli, Italy
Nationality: Italian
Languages: Italian, English
Married: Two children

Home Address:
Via Apuania 31, 00162 Rome
☎: +39 (06) 4420 2177 +**39-339-6825451**

Office Address:
Translational Oncogenomics Unit
Italian National Cancer Institute, Rome “Regina Elena”
Via Elio Chianesi 53
00144-Rome
Italy
☎: +39 (06) **52665327/2911**
Fax: +39 (06) **52662880**
E-mail: blandinog@ifo.it, gblandinog@activep53.eu

Academic History

Education

Degrees

M.D.	University of Catania, Italy, 1990
Residency Program (Oncology)	University of Milan, National Cancer Institute, Milan, Italy, 1994

Awards

1991 The Italian Association for Cancer Research (AIRC) Fellowship for postdoctoral research.

1993 The Regina Elena Cancer Institute Fellowship for postdoctoral research.

1995 The Italian Association for Cancer Research (AIRC) International Fellowship for postdoctoral research.

1996 The Feinberg Postdoctoral Fellowship, Weizmann Institute of Science

1999 Young Scientist Fellowship From Telethon.

Employment History

Associate Professor, Department of Oncology, McMaster University, Hamilton Canada, 1st March 2012

Director of Traslational Oncogenomic Laboratory, Italian National Cancer Institute Regina Elena, Rome Italy, April 2008 –

Institutional Research Coordinator, Translational Oncogenomics Unit, Italian National Cancer Institute Regina Elena, Rome Italy, April 2007 –2011

Institutional Research Coordinator, Department of Molecular Cell Biology, Italian National Cancer Institute Regina Elena, Rome Italy, July 2007

Visiting Scientist, Ludwig Institute for Cancer Institute, University of Oxford, England, September 2010

Fellow Scientist, Department of Molecular Cell Biology Laboratory, Weizmann Institute of Science, Rehovot Israel, September 2005

Medical Researcher, Department of Experimental Oncology, Italian National Cancer Institute Regina Elena, Rome Italy, January 2002- 2008

Visiting Scientist, Department of Nephrology, Mount Sinai Institute, New York, USA, June 2001

Telethon Young Fellow, Molecular Oncogenesis Laboratory, Italian National Cancer Institute Regina Elena, Rome Italy, 1999-2001

Postdoctoral Fellow, Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel, 1995-1999

Postdoctoral Fellow, Italian National Cancer Institute Regina Elena, Rome Italy, 1991-1995

Fellow, Institute of Pathology, University of Catania, Italy, 1990-1991

Research Student, Institute of Pathology, University of Catania, Italy, 1986-1990

Licensing

License to practice Medicine in Italy, 1990

Professional Organizations (past and present)

Committee Member: ISF-Israel National Foundation; BSF-Binational USA-Israel Foundation; CMRH-Netherland Cancer Research; Austrian Cancer Society-Fellowship and Grant Program; Career Program (Associate Professorship) University of Singapore; Dutch Cancer Society; German-Israel Society, North West Cancer Research Fund., AICR, UICC Fellowship Program, Cancer Research UK, AFM-Genethon, Foundation for Polish Science, Weizmann Institute of Science, Health Research Board (HRB) Ireland.

Journal Reviewer and Editorship

Deputy Editor: Journal of Experimental and Clinical Cancer Research

Editorial Board Member: The Open Cell Signaling Journal; Journal of Experimental and Clinical Cancer Research; The International Journal of Low Radiation; The European Journal of Clinical and Medical Oncology; World Journal of Otorhinolaryngology (WJO);

Reviewer for the following journals: Molecular Cell; PNAS, Blood; Molecular Cell Biology; Cancer Research; Oncogene; Nucleic Acid Research, Cell Death and Differentiation; Molecular Biology of Cell; Genome Biology, Molecular Medicine, Cell Cycle; Leukemia, BMC Molecular Biology; Journal Cell Science, Proteins, FEBS Letters; Journal of Molecular Biology; Experimental Cell Research; British Journal of Pharmacology; Int. Journal of Cancer; Cancer Letters, Molecular Carcinogenesis; Archives Journal of Dermatology; European Journal of Cancer; Cell Proliferation, The Open Cell Signaling Journal, Cell Tissue and Research; BBA; Int. J. of Biochem. Cell. Biol; Oncology; Nature Communications; Tumor Biology; BMC Chemical Biology; Annals of Otolaryngology, Rhinology and Laryngology; Breast Cancer Research and Treatment.

Academic Teaching

Harvard University: University Graduate School Courses

Translational Research Methods and Applications (accepted proposed course 2010)

University lectures at “La Sapienza” University in Rome and University of Trieste.

Teaching Experience

Teacher Basic Science in Oncology (lectures) University La Sapienza (Rome, Italy)

Teacher, experimental course “Cell cycle and apoptosis”, organized by the international School of Oncology and Experimental Medicine (Rome 1-4 December, 1994)

Supervisorships

Graduate Students

Sara Donzelli, M.Sc., University of Rome “La Sapienza”, Faculty of Mathematical, Physical and Natural Sciences, 3 year Degree in Biological Science, Thesis entitled “*Producing cancer cell lines expressing protein mutant p53 stability*”, Rome, Italy, 2002-2005

Sara Donzelli, M.Sc., University of Rome “La Sapienza”, Faculty of Mathematical, Physical and Natural Sciences, Specializing in Applied Biology in Biomedical Research, Thesis entitled “*Oncogenomic Approaches in Exploring Gain of Function of Mutant p53*”, Rome, Italy, 2005-2007

Federica Ganci, M.Sc., University of “Tor Vergata”, Thesis entitled “*The mutant protein p53His175 controls miR.128b expression in a human large-cell lung cancer cell line*”, Rome, Italy, 2007- 2008

Olimpia Monti, M.Sc., University of “Tor Vergata”, Thesis entitled “*p73, p63 and mutant p53: members of protein complexes floating in cancer cells*”, Rome, Italy, 2001- 2002

Ph.D Doctoral Students

Olimpia Monti, M.Sc., University of “Tor Vergata”, Ph.D Thesis entitled “*The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs*”, Rome, Italy, 2003- 2006

Eleonora Lapi, M.Sc., University of “Tor Vergata”, Ph.D in Molecular and Cellular Biology, Thesis entitled “*Identification of novel and direct target genes of p73*”, Rome, Italy, 2004- 2007

Efrem Bertini, M.Sc., University of “Tor Vergata”, Ph.D in Biochemistry and Molecular Biology, Thesis entitled “*Yap is regulated by phosphorylation at the G2/M transition*”, Rome, Italy, 2006- 2009

Sara Donzelli, M.Sc., University of Rome “La Sapienza”, Faculty of Mathematical, Physical and Natural Sciences, Ph.D in Genetics and Molecular Biology, Thesis entitled “*Study of mutant p53 protein gain of function by microRNAs modulation*”, Rome, Italy, 2007-2011

Sergio Galanti, M.Sc., University of Rome “La Sapienza”, Faculty of Biology and Biotechnology “Charles Darwin”, Ph.D in Cell and Developmental Biology, Thesis entitled “*Identification of VDR transcriptional signatures in breast cancer cells by ChIP-on-chip analysis*”, Rome, Italy, 2008-2011

Federica Ganci, M.Sc., Ph.D in Cellular and Molecular Biology, University of Tor Vergata, Ph.D Thesis entitled “*microRNAs expression profiling in HNSCC and their correlation with TP53 status*”, Rome, Italy, 2008-2011

Fabio Valenti, M.Sc., “University of Messina”, Faculty of Mathematical, Physical and Natural Sciences, Ph.D in Neuroscience, Medicine School University of Messina, Thesis entitled “*Peptide targeted therapies for the treatment of human cancers with mutations of the p53 gene*”, Messina, Italy, 2006-2010

Francesca Fausti, Ph.D in Endocrinology and Molecular Medicine, Thesis entitled “*Role of YAP in apoptosis and senescence processes*”, Rome, Italy, 2006-2010

Francesca Biagioni, M.Sc., University of Rome “La Sapienza”, PhD school in Biology and Molecular Medicine, PhD programme in Immunological Sciences, Thesis entitled “*The advent of microRNAs in the molecular taxonomy of breast cancer*”, Rome, Italy, 2006-2009

Stefania Dell’Orso, M.Sc., PhD in Endocrinology and Molecular Medicine, Faculty of Medicine, University of Rome “La Sapienza”, Thesis entitled “*Application of ChIP on chip analysis to the identification of mutant p53 target genes*”, Rome, Italy, 2006-2009

External Supervisory PhD Committees

Raffaella Santoro, Ph.D in Molecular Oncology, Thesis entitled “*The Histone Acetyl Transferase Tip60 regulates the proapoptotic activities of the transcription factor E2F1*”, University of Southern Denmark, Odense, Denmark 2008 (Opponent).

Ying Zhao, Ph.D, Thesis entitled “*Pharmacological Targeting of p53 Pathway Alterations in Tumors*”, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden 2010 (Opponent).

Jinfeng Shen, Ph.D, Thesis entitled “*Rescue of mutant p53 family members by the low molecular weight compound PRIMA-1^{MET}/APR-246*”, Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden 2010 (Opponent).

Marco Napoli, Ph.D in Molecular Biomedicine, Thesis entitled “*A Pin1/mutant p53 axis promotes aggressiveness in breast cancer*”, Università degli Studi di Trieste, Trieste, Italy 2010 (Opponent).

Organization of International conferences

- 1) Making decisions in G1, Frascati, Italy 2002.
- 2) 1st International p73/p63 Workshop, Rome, Italy 2002.

- 3) 2nd International p73/p63 Workshop, Rome, Italy 2004.
- 4) P53 Marathon, Ein Gedi, Israel, 2005.
- 5) 3rd International p73/p63 Workshop, Rome, Italy 2007.
- 6) P53 Marathon, Lyon, France 2007.
- 7) P53 Marathon, Acre, Israel 2009;
- 8) The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, Rome, Italy 22-23 April, 2009. *Published: Blandino G, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor pathway: a brainstorming workshop. Sci Signal. 2009 Nov 3;2(95):mr6.*
- 9) The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, Ariccia (Rome), Italy, 2-5 November 2010. *Published: McNeill H, Sudol M, Halder G, Strano S, Blandino G, Shaul Y. The Hippo tumor suppressor pathway: a report on "The Second Workshop On The Hippo tumor suppressor pathway". Cell Death Differ. 2011 Aug;18(8):1388-90.*
- 10) 5th Mutant p53 Workshop: "From bench to bedside across mouse models", Ariccia (Rome), Italy, 24th May, 2011. *Published: Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. "Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop". Cell Death Differ. 2012 Jan;19(1):180-3.*
- 11) Keystone Symposium "The HIPPO Tumor Suppressor Network: from organ size control to stem cells and cancer", Monterey, CA, USA 19-23 May 2013 (Organizers: Dr. Sudol, Dr. Blandino, Dr. Halder, Dr. McNeil).

Grant Funding

Principal Investigator

"Epigenetic and metabolic alterations in cancer pathogenesis" **Blandino G, PI**; Euros **400,000**, Italian Ministry for Research and University 2011-2014

"Profile of microRNA expression and CpG Island methylation in tissue samples from mesothelioma patients" **Blandino G, PI**; Euros **600,000** Italian National Institute for Occupational Disease Prevention 2010-2012

European Union 6th Framework "Integrated Project Active p53", **Blandino G, Scientific Coordinator** ; Euros **6,000,000.000** 2004-2009 (extended 2012)

"Molecular signature as predictor of breast cancer occurrence" **Blandino G, PI**; Euros **150,000** Veronesi Foundation 2010-2012

"p53 family interaction network as a target of anti-tumoral peptide therapy" **Blandino G, PI**; Euros **115.000** Pascale Foundation. 2008-2011

"Exploring transcriptional activity of gain of function Mutant p53 protein" **Blandino G, PI**; Euros **330,000** AIRC. 2007-2011

"Linking transcriptome to proteome: Functional oncogenomics for diagnosis and treatment of human cancer" **Blandino G, PI**; Euros **3,000,000** AIRC 2004-2011

Co-Investigator

“Global epigenomic profiling of normal and diseased cells for the diagnosis of normal and diseased cells for diagnosis of hematological malignancies” **Blandino G**, Co-Investigator; Euros 120,000 European Institute of Oncology 2010-2012

“New peptides as cell cycle regulators in chemotherapy for epithelial and skin cancer” **Blandino G**, Co-Investigator; Euros 150,000 Italian Institute for Dermatology 2007-2011

European Union 6th Framework: “Research unit of the Integrated Project “Mutp53” Prof. Klas Wiman and Prof. Moshe Oren (PI); **Blandino G**, Co-Investigator; Euros 240.933,50 2004

Grant Support for the conduction of the laboratory

The work in Dr. Blandino’s laboratory is supported by:

Italian Ministry of Health: Euros 122,000.00

Italian Association for Cancer Research (AIRC): Euros 110,000.00

ACC-Italy-USA : Euros 90,000.00

Italian Ministry for Research and University: Euros 435,000.00

Patents, National and International

1. **Inventors: Giovanni Blandino**, Gennaro Citro, Rossella Maria Galati, Alessandra Verdina.

Number and date of deposit in Italy: MI2004A002227, 19 November 2004

This invention allows "Peptides to be able to break 53/p63, m-p53/p73 and m-p53/respective isoform proteins complex formed in the tumor cells and there uses in the pharmacological field". In addition, this invention uses a method that provokes the disruption of complex proteins found in the cancer cell lines in vitro. Furthermore, these peptides are used in preparing anti-cancer medicine. Iter: 2007 Deposited permit request on a National/European level + permit requested in Israel, Singapore, the USA and EU. 2008 permit request made in Germany. 2010 Entered PCT national phase in the USA. 2011 Granted the PCT process in Japan

2. **Inventors: Giovanni Blandino**, Gennaro Citro, Sabrina Strano, Silvia Di Agostino.

Number and date of deposit in Italy: RM 2009A232 del 11/05/2009.

The present invention concerns peptide able to disrupt the protein complex between HIS273 mutated p53 protein and oncosuppressive p73 protein in tumor cells and uses hereof in medical field. More particularly, the present invention concerns a SIMP peptide (Short-interfering mutant p53 peptides) suitable to

disrupt the protein complexes within tumor cells resulting from m-p53 and p73 proteins selectively in tumors wherein m-p53 contains HIS273 mutation. Iter: 2010 deposited international permit request

Publications in Peer-Reviewed Journals:

- 1) Callari D, Gasso G, **Blandino G**, Billitteri A. Azione del retinolo su colture di hepatoma H4. Boll. Soc. It. Biol. Sper. N11., 1989.
- 2) Callari D, **Blandino G**, Saccone V, D'Amico C, Billitteri A. Azione del retinolo sul recupero di cellule vitali e sul potenziale clonogenico di cellule HTC ipertermizzate in vitro. Boll. Soc. It. Biol. Sper. N.12, 1992.
- 3) Callari D, **Blandino G**, Saccone V, D'Amico C, Billitteri A. Azione dell'ipertermia e del trattamento con retinolo in vitro sull'adesività alla laminina ed alla fibronectina delle cellule HTC. Boll. Soc. It. Biol. Sper. N.12; 1992.
- 4) Callari D, Strano S, **Blandino G**, Saccone V, and Billitteri A. Adhesion to some extracellular matrix components of heat-treated HTC hepatoma cells. J. Exp. Clin. Cancer Res. 13: 2, 1994.
- 5) Strano S, Callari D, Billitteri A, and **Blandino G**. Fibronectin and Vitronectin Adhesion enhancement during U937 cells differentiation induced by IL-6 and LIF. J. Exp. Clin. Cancer Res., 13, 4, 1994.
- 6) Soddu S, **Blandino G**, Citro G, Scardigli R, Piaggio G, Ferber A, Calabretta B, and Sacchi A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood, 83, 8, 1994.
- 7) Strano S, and **Blandino G**. Apoptosis: cell death or suicide. This is the problem! J. Exp. Clin. Cancer Res., 14, 3, 1995.
- 8) **Blandino G**, Scardigli R, Rizzo MG, Crescenzi M, Soddu S, and Sacchi A. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene, 10, 731-737, 1995.
- 9) Soddu S, **Blandino G**, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M, and Sacchi A. WT-p53 induces diverse effects in 32D cells expressing different oncogenes. Molecular and Cellular Biology, 16, 2, 487-495, 1996. (The two first authors contributed equally to this work).
- 10) Soddu S, **Blandino G**, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M, and Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. The Journal of Cell Biology, 134, 1, 193-204, 1996.
- 11) Martinelli R, **Blandino G**, Scardigli R, Crescenzi M, Lombardi D, Sacchi A, and

- Soddu S. Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. *Oncogene* 15, 607-611, 1997
- 12) Shaulian E, Resnitzky D, Shifman O, **Blandino G**, Amsterdam A, Yayon A, and Oren M. Induction of Mdm2 and enhancement of cell survival by bFGF. *Oncogene* 15, 2717-2725, 1997.
 - 13) Scardigli R, Bossi G, **Blandino G**, Crescenzi M, Soddu S, and Sacchi A. Exogenous wt-p53 overexpression does not affect normal hematopoiesis: basis for bone marrow purging? *Gene Therapy* 4, 1371-1378, 1997.
 - 14) **Blandino G**, and Strano S. Bcl-2: the pendulum of the cell fate. *J. Exp. Clin. Cancer. Res.*, 16, 1, 1997
 - 15) Rizzo M.G, Zepparoni A, Cristofanelli B, Scardigli R, Crescenzi M, **Blandino G**, Giuliacci S, Ferrari S, Soddu S and Sacchi A. Wtp53-action in human leukemia cell lines corresponding to different stages of differentiation. *British Journal of Cancer* 77, 1429-1438, 1998
 - 16) Wang Y, **Blandino G**, Oren M, and Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differently modifies the cytotoxicity of anticancer drugs. *Oncogene* 17, 1923-1930, 1998.
 - 17) **Blandino G**, Levine AJ, and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. *Oncogene* 18, 477-485, 1999.
 - 18) Wang Y, **Blandino G**, and Givol D. Induced p21 waf1 expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. *Oncogene* 18, 2643-2649, 1999.
 - 19) Agami R, **Blandino G**, Oren M, Shaul Y. Interaction of c-Abl and p73 α and their collaboration to induce apoptosis. *Nature* 399, 809-813, 1999.
 - 20) Cerone M.A, Marchetti A, Bossi G, **Blandino G**, Sacchi A, and Soddu S. p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblast. *Cell Death and Differentiation* 7, 506-508, 2000
 - 21) Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine A.J, Sacchi A, Cesareni G, Oren M and **Blandino G**. Physical and functional interaction between p53 mutants and different isoforms of p73. *J. Biol. Chem.* 275, 29503-29512, 2000
 - 22) Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A and **Blandino G**. From p63 to p53 across p73. *FEBS Letters*, 490, 163-170, 2001.
 - 23) Strano S, Munarriz E, Rossi M, Cristofanelli B, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G and **Blandino G**. Physical interaction with Yes-

- associated protein (YAP) enhances p73 transcriptional activity. *J. Biol. Chem.*, 276, 15164-15173, 2001.
- 24) Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, and **Blandino G**. The transcriptional repressor ZEB regulates p73 expression at the cross-road between proliferation and differentiation. *Mol. Cell. Biol.*, 24, 8461-8470, 2001.
- 25) Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole P, Fontemaggi G, Fanciulli M, Schiltz L, **Blandino G**, Balsano C, and Levrero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. *Mol. Cell*, 9, 175-186, 2002.
- 26) Le Bras M, Delattre V, Bensaad K, **Blandino G**, and Soussi T. Monoclonal antibodies raised against Xenopus p53 interact with human p73. *Oncogene*, 14, 1304-1308, 2002.
- 27) Morena A.R, Riccioni S, Marchetti A, Tartaglia Polcini A, Mercurio A.M, **Blandino G**, Sacchi A, and Falcioni R. Expression of $\beta 4$ integrin subunit induces monocytic differentiation of 32D/v-Abl cells. *Blood*, 100, 96-106, 2002
- 28) Strano S, Fontemaggi G, Costanzo A, Rizzo M.G, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M and **Blandino G**. Physical interaction with human tumor derived p53 mutants inhibits p63 activities. *J. Biol Chem.* 277, 18817-18826, 2002
- 29) Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, and **Blandino G**. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. *J. Biol Chem.* 277, 43359-43368, 2002
- 30) Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, **Blandino G**, Schneider C, and Del Sal G. The Prolyl-Isomerase Pin1 reveals a new mechanism to control p53 functions following genotoxic insults. *Nature*, 419, 853-857, 2002
- 31) Bensaad K, Le Bras M, Unsal K, Strano S, **Blandino G**, Tominaga O, Rouillard D and Soussi T. Change of conformation of the DNA binding domain of p53 is the only key element for binding and interfering with p73. *J. Biol. Chem.* 278, 10546-10555, 2003.
- 32) Strano S, and **Blandino G**. p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53 proteins. *Cell Cycle* 2, 348-349, 2003.
- 33) Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, **Blandino G**, Balsano C., Lavia P, and Levrero M. p73 is regulated by phosphorylation at the transition G2/M. *J. Biol. Chem.*, 278, 49196-49202, 2003.
- 34) Di Stefano V, **Blandino G**, Sacchi A, Soddu S, and G. D' Orazi. HIPK2 counteracts MDM2 inhibition of p53 by interfering with its ubiquitination and nuclear export. *Oncogene* 231, 5185-5192, 2004.

- 35) Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, **Blandino G**, and Del Sal G. Pin1 links the activities of c-Abl and p300 in regulating p73 function. *Molecular Cell*, 14, 625-636, 2004.
- 36) **Blandino G** and M. Dobbelstein. p73 and p63-why do we still need them? *Cell Cycle* 3, 886-894, 2004
- 37) Rizzo M.G, Giombini E, Diverio D, Vignetti M, Testa U, Sacchi A, Lo Coco F, and **Blandino G**. Analysis of p73 expression in acute myeloid leukemias: lack of DN-p73 expression is a frequent feature of acute promyelocytic leukemia. *Leukemia* 18, 1804-1809, 2004.
- 38) Dobbelstein M, Strano S, Roth J, and **Blandino G**. p73-induced apoptosis: a question of compartments and cooperation. *Biochem. Biophys. Res. Commun*, 331, 688-693, 2005.
- 39) Strano S, Monti O, Pediconi N, Baccharini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, and **Blandino G**. The transcriptional co-activator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. *Molecular Cell*. 18, 447-459, 2005.
- 40) Fontemaggi G, Gurtner A, Damalas A, Higashi Y, Sacchi A, Strano S, Piaggio G and **Blandino G**. δ EF1 repressor controls selectively p53 family members during differentiation. *Oncogene*. Nov. 10; 24(49):7273-80, 2005.
- 41) Merlo P, Fulco M, Costanzo A, Mangiacasale R, Strano S, **Blandino G**, Taya Y, Lavia P. and Levrero M. p73 role in mitotic exit. *J. Biol. Chem.* 280, 30354-30360, 2005.
- 42) Bossi G, Lapi E, Strano S, Rinaldo C, **Blandino G**, and Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. *Oncogene* Jan 12 ; 25 (2):304-9, 2006.
- 43) Belloni L, Moretti F, Damalas A, Costanzo A, **Blandino G**, and Levrero M. Δ Np73 α protects myogenic cells from apoptosis. *Oncogene* Jun.15 ;25 (25):3606-12, .2006.
- 44) Lapi E, Iovino A, Fontemaggi G, Soliera R, Iacovelli S, Sacchi A, Rechavi G, Givol D, **Blandino G*** and Strano S. S100A2 is a direct transcriptional target of p53 homologues during keratinocyte differentiation (*corresponding author) *Oncogene* Jun.22 ;25 (26):3628-37, 2006.
- 45) Giombini E, **Blandino G**, Sacchi A, Lo Coco F, and Rizzo M.G. The complexity of p73 isoforms in human neoplasia. *Gene Ther. Mol. Biol.* 9:1-16, 2005.
- 46) Hoshino M, Qi M, Yoshimura M, Miyashita T., Tagawa K, Wada Y, Enokido Y, Marubuchi S, Harjes P, Arai N, Oyanagi K, **Blandino G**, Sudol M, Rich T, Kanazawa I, Wanker E.E, Saito M, and Okazawa H. Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. *J. Cell Biology* Feb. 589-604, 2006.

- 47) Di Agostino S, Strano S, Emiliozzi V, Sacchi A, **Blandino G***, Piaggio G. Gain of function of mutant p53: the mutant p53/NFY protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. (*corresponding author) *Cancer Cell Sep.10 (3):191-202, 2006.*
- 48) Strano S, Dell'Orso S, Mongiovì A, Monti O, Lapi E, Di Agostino S, Fontemaggi G and **Blandino G**. Mutant p53 proteins: between loss and gain of function. *Head and Neck 29:488-96, 2007*
- 49) Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, and **Blandino G**. Mutant p53: an oncogenic transcription factor. *Oncogene 26:2212-9, 2007.*
- 50) Weisz L, Damalas A, Lontos M, Karakaidos P, Fontemaggi G, Kalis M, Levrero M, Strano S, Gorgoulis W.G, Rotter V, **Blandino G**, Oren M. Mutant p53 enhances NF-kB activation by tumor necrosis factor alpha in cancer cells. *Cancer Research 67:2396-401, 2007*
- 51) **Blandino G**, Fanciulli M, Levrero M, Piaggio G. The Post Genomic Era: Workshop on Chromatin Immunoprecipitation related techniques. *Cell. Death and Diff. 14:1390-1391, 2007*
- 52) Mainardi S, Palescandolo E, Fontemaggi G, Diverio D, Grignani F, Testa U, Sacchi A, Lo Coco F, Levrero M, **Blandino G*** and Rizzo MG. DNp73 is a transcriptional target of PML/RAR α oncogene (*corresponding author) *Cell Death and Differentiation 14:1968-71, 2007*
- 53) Strano S, and **Blandino G**. YAP meets tumor suppression. *Mol. Cell, 27:863-4, 2007*
- 54) Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, **Blandino G.**, Givol D, D'Orazi G. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. *Cancer Res. May 15;68(10):3707-14, 2008*
- 55) Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, **Blandino G.**, Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. *Cell Cycle. Jun 15;7(12):1870-9, 2008*
- 56) Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, **Blandino G**. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. *Cell Cycle. Nov 1;7(21):3440-7, 2008*
- 57) **Blandino G**. Mitosis poisons p53. *Cell Cycle. Nov 1;7(21), 2008*
- 58) Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, **Blandino G**. PML, YAP, and p73 are components of a

proapoptotic autoregulatory feedback loop. *Mol Cell*. Dec 26;32(6):803-14, 2008

- 59) Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, **Blandino G**. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. *Curr Genomics*. May;9(3):200-7, 2008
- 60) Benassi B, Strano S, **Blandino G**. Tetraploidy triggers mitochondria. *Cell Cycle*. May 1;8(9):1305-6, 2009
- 61) **Blandino G**, Moll UM. p63 regulation by microRNAs. *Cell Cycle*. May 5;8(10):1466-7, 2009
- 62) Haupt S, Di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, **Blandino G**, Haupt Y. Promyelocytic leukemia protein is required for gain of function by mutant p53. *Cancer Res*. Jun 1;69(11):4818-26, 2009
- 63) Bertini E, Oka T, Sudol M, Strano S, **Blandino G**. YAP: at the crossroad between transformation and tumor suppression. *Cell Cycle*. Jan 1;8(1):49-57, 2009
- 64) Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, **Blandino G**, Mottolese M, Falcioni R. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. *Cancer Res*. Jul 15;69(14):5978-86, 2009
- 65) Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, **Blandino G**. Metformin, diet and breast cancer: an avenue for chemoprevention. *Cell Cycle*. Aug 15;8(16):2661, 2009
- 66) Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F, **Blandino G**, Levrero M, Rizzo MG. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. *Oncogene*. Nov 12;28(45):4034-40, 2009
- 67) Fontemaggi G, Dell'Orso S, Trisciuglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, **Blandino G**. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. *Nat Struct Mol Biol*. Oct;16(10):1086-93, 2009
- 68) Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M, Piacentini M, **Blandino G**, Costanzo A, Sakaguchi K, Tuosto L. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. *Cell Cycle*. Oct 15;8(20):3396-405, 2009

- 69) Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, **Blandino G**, Gallucci M, Lauria R, Malorni L, Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. *J Exp Clin Cancer Res.* Oct 8;28:135, 2009
- 70) **Blandino G**, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor pathway: a brainstorming workshop. *Sci Signal.* Nov 3;2(95):mr6, 2009
- 71) Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, **Blandino G**, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. *Cancer Cell.* Mar 16;17(3):273-85, 2010
- 72) Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalg Ri, Tarcic G, Bossel N, Zeisel A, Amit I, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano, **Blandino G**, Børresen-Dale A, Pilpel Y, Yakhini Z, Segal E and Yarden Y. EGF Decreases the abundance of microRNAs that restrain oncogenic transcription factors. *Sci. Signal.* Jun 1;3(124):ra43, 2010
- 73) Cioce M, Gherardi S, Viglietto G, Strano S, **Blandino G**, Muti P and Ciliberto G. Enriched mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like targeting drugs. *Cell Cycle.* Jul 15;9(14):2878-87, 2010
- 74) Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Floridi A, Passananti C, **Blandino G**, and Fanciulli M. Che-1 depletion inhibits mutant p53 expression and activates p73-dependent apoptosis by inducing endogenous DNA damage in human breast cancer. *Cancer Cell.* Aug 9;18(2):122-34, 2010
- 75) Slee E, Benassi B, Goldin R, Zhong S, **Blandino G**, and Lu X. Phosphorylation of Ser312 contributes to tumour suppression by p53 in vivo. *Proc Natl Acad Sci U S A.* Nov 9;107(45):19479-84, 2010
- 76) Santoro R, **Blandino G**. p53: The pivot between cell cycle arrest and senescence. *Cell Cycle.* Nov;9(21):4262-3, 2010
- 77) Fontemaggi G, Dell'Orso S, Muti P, **Blandino G** and Strano S. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. *Cell Cycle.* Jun 15;9(12):2464-6, 2010
- 78) Strano S and **Blandino G**. Stability strengths oncogenic activity. *Cell Cycle.* Apr 15;9(8):1458-9, 2010
- 79) Goeman F, **Blandino G**. Novel insights into the cytoplasmic functions of p53. *Cell Cycle.* Jul 1;9(13):2498, 2010
- 80) Dell'Orso S, Ganci F, Strano S, **Blandino G**, and Fontemaggi G. ID-4: a new player in the cancer arena. *Oncotarget.* May;1(1):48-58, 2010

- 81) Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Damalas A, Levrero M, Strano S, Rotter V, Oren M and **Blandino G**. CHIP on chip analysis of in vivo mutant p53 binding to selected gene promoters. *OMICS*. May;15(5):305-12, 2011
- 82) Muti P, Benassi B, Falvo E, Santoro R, Galanti S, Citro G, Carrubba G, **Blandino G**, and Strano S. Omics underpins novel clues on VDR chemoprevention target in breast cancer. *OMICS*. Jun;15(6):337-46, 2011
- 83) Ganci F, Conti S, Fontemaggi G, Manciocco V, Donzelli S, Covello R, Muti P, Strano S, **Blandino G**, Spriano G. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors. *OMICS*. Jun;15(6):375-81, 2011
- 84) Testoni B, Guerrieri F, Gerbal-Choine S, **Blandino G** and Levrero M. p53-paralog DNp73 oncogene is repressed by IFN α /STAT2 through the recruitment of the Ezh2 Polycomb Group transcriptional repressor. *Oncogene*. Jun 9;30(23):2670-8. doi: 10.1038/onc.2010.635, 2011
- 85) Sieri S, Muti P, Agnoli C, Berrino F, Pala V, Grioni S, Abagnato CA, **Blandino G**, Contiero P, Schunemann H, Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. *Int J Cancer*. Feb 15;130(4):921-9, 2011
- 86) Testoni B, Voellenke C, Guerrieri F, Gerbal-Chaloin S, **Blandino G**, Levrero M. Chromatin dynamics of gene activation and repression in response to ifn{alpha} reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. *J Biol Chem*. Jun 10;286(23):20217-27, 2011
- 87) McNeill H, Sudol M, Halder G, Strano S, **Blandino G**, Shaul Y. Meeting Report The Hippo tumor suppressor pathway: a report on the Second Workshop on the Hippo tumor suppressor pathway. *Cell Death and Differentiation*. Aug;18(8):1388-90. doi: 10.1038/cdd.2011.61, 2011
- 88) Di Agostino S, Strano S, **Blandino G**. YAP1 (Yes-associated protein 1, 65kDa). *Atlas Genet Cytogenet Oncol Haematol*. January 2010
- 89) Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Soussi S, Mazzoni C, **Blandino G** and Tuosto L. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. *J. Biol. Chem*. Sept 27, asdoi:10.1074/jbc.M111.279539, 2011 (Epub ahead of print)
- 90) Botti E, Spallone G, Moretti F, Marinari B, Pinetti V, Galanti S, De Meo PD, De Nicola F, Ganci F, Castrignanò T, pesole G, Chimenti S, Guerrini L, Fanciulli M, **Blandino G**, Karin M, Costanzo A. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. *Proc Natl Acad Sci U S A*. Aug 16;108(33):13710-5, 2011
- 91) Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D'Alessia D, Muti P, **Blandino G**, Sperduti I, Pinnarò P. Dose and polymorphic genes *xrcc1*, *xrcc3*, *gst paly* a role in the risk of article developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. *BMC*

Cancer. Jul 12;11:291, 2011

- 92) Santoro R, Marani M, **Blandino G**, Muti P, Strano S. Melatonin triggers p53^{Ser} phosphorylation and prevents DNA damage accumulation. *Oncogene* Oct 17. doi: 10.1038/onc.2011.469, 2011(Epub ahead of print)
- 93) **Blandino G**, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K and Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop. *Cell Death & Differentiation*. Jan;19(1):180-3, 2012
- 94) Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, **Blandino G**, Cioce M. SASP mediates chemoresistance and tumor-initiating-activity of Mesothelioma cells. *Oncogene* Oct 24. doi: 10.1038/onc.2011.485, 2011 (Epub ahead of print)
- 95) Cioce M, Canino C, Muti P, Strano S, **Blandino G**. Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells. *Cell Cycle*. Jan 1;11(1):132-40, 2012
- 96) Benassi B, Flavin R, Marchionni L, PanY, Chowdhury D, Marani M, Strano S, Muti P, **Blandino G**, and Loda M. c-Myc is activated via USP2a-mediated modulation of microRNAs in prostate cancer. *Cancer Discov*. 2012 Mar;2(3):236-247 (co-corresponding author)
- 97) Cioce M, **Blandino G**. PGC1 α Confers Specificity - Metabolic Stress and p53-Dependent Transcription. *Molecular Cell*. Nov 18;44(4):515-6, 2011
- 98) Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, **Blandino G**. microRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. *Cell Death and Differentiation* Jun;19(6):1038-48, 2012
- 99) Valenti F, Fausti F, Biagioni F, Fontemaggi G, Shay T, Domany E, Yaffe MB, Strano S, **Blandino G**, Di Agostino S. Mutant p53 oncogenic functions are sustained by plk2 kinase through an autoregulatory feedback loop. *Cell Cycle*. Dec 15;10(24):4330-40, 2012 (co-corresponding author)
- 100) Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Bergamo P, Anichini A, Sabapathy K, McCubrey J, Ricciardi MR, Tafuri A, **Blandino G**, Orlandi A, Cognetti F, De Maria R, Del Bufalo D, Milella M. The mitogen activated protein kinase (MARK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. *Journal of Molecular Medicine*. Jan 4, 2012
- 101) Falvo E, Strigari L, Citro G, Giordano C, Boboc G, Fabretti F, Bruzzaniti V, Bellesi L, Muti P, **Blandino G**, Pinnarò P. SNPs in DNA repair or Oxidative Stress Genes and Late Subcutaneous Fibrosis in Patients following a Single Shot Partial Breast Irradiation. *JECRCR*. Jan 24;31:7, 2012

- 102) **Blandino G***, Valerio M*, Cioce M*, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, Manetti C, Gennaro Citro G, Muti P, Strano S. Metformin elicits anticancer effects through the sequential modulation of DICER, microRNAs and c-MYC. *Nat Commun.* 2012 May 29;3:865 (corresponding author)
- 103) Cordelli, E, Eleuteri, P, Grollino, M, Benassi, B, **Blandino, G**, Bartoleschi, C, Pardini, M, Di Caprio, E, Spanò, M, Pacchierotti, F, Villani, P. Direct and delayed X-ray induced DNA damage in male mouse germ cells. *Environ Mol Mutagen.* 2012 Jul;53(6):429-39
- 104) Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E and **Blandino G**. miR-10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumors. *EMBO Mol Med.* 2012 Nov;4(11):1214-29.
- 105) Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Di Agostino S, Cambria A.M., Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A and **Blandino G**. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. *Cell Death Dis.* 2012 Nov 15;3:e423
- 106) Fausti F, Di Agostino S, Sacconi A, Strano S, **Blandino G**. Hippo and rassf1a Pathways: A Growing Affair. *Mol Biol Int.* 2012;2012:307628 1.
- 107) Santoro R, Marani M, **Blandino G**, Muti P, Strano S. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. (*Carcinogenesis*, published online 25th Jan 2013).
- 108) Santoro R, Marani M, Blandino G, Muti P, Strano S. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. (*Carcinogenesis*, published online 25th Jan 2013).

Chapters in Books

1. Rizzo M.G, Soddu S, Crescenzi M, **Blandino G**, Scardigli R, Coen S, Sacchi A. Wild-type p53 overexpression diversely affects different leukemia cells. Proceedings of the XVI International Cancer Congress 1994. New Delhi (India), October 30-November 5, 1994. Monduzzi Editore
2. Monti O, Damalas A, Strano S, and **Blandino G**. p73, p63 and mutant p53: members of protein complexes floating in cancer cells. Book for “25 years of p53 research” by Kluwer Academic Publishers. 2005
3. **Blandino G**. Gain of function p53. *Encyclopedia of Cancer*, 2nd edition by Springer Publisher. 2008

4. Ganci F, Sacconi A, Manciooco V, Spriano G, Fontemaggi G, **Blandino G**. Molecular genetics and biology of head and neck squamous cell carcinoma: implications for diagnosis, prognosis and treatment. *Head and Neck Cancer* (ISBN 979-953-307-914-0). 2012
5. **Blandino G** and Fontemaggi G. Id4 (Inhibitor of DNA binding). *Encyclopedia of Signaling Molecules*. Springer. 2012
6. Goeman F, Fontemaggi G, **Blandino G**. ChIP-on-chip to identify mutant p53 targets. *p53 Protocols: Second edition*. Humana Press (Springer). 2012
7. Donzelli S, Strano S, **Blandino G**. Yap and p73: a matter of mutual specificity in tumor suppression. *The Hippo Signaling pathway and cancer*. Springer (in press, 2012)

Letters (peer-reviewed)

- 1) Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, **Blandino G**. *Metformin, diet and breast cancer: An avenue for chemoprevention*, *Cell Cycle*. 8:16, 1-1; 15 August, 2009

Invited Presentations (selected)

National and International Meetings (selected)

- 1) Speaker: *The Mutp53 Consortium Kick-Off Meeting*, Lillehammer, Norway, 2004
- 2) Speaker: *First IEO-IFOM Cancer Meeting*, Milan, Italy 2004
- 3) Speaker: *26th Meeting of the European Study Group for Cell Proliferation (ESGCP)*, Prague, Czechoslovakia 2004
- 4) Speaker: *OECI 25th Annual Meeting*, Berlin, Germany 2004
- 5) Speaker: *The Active p53 Consortium Kick-Off Meeting*, Ghent, Belgium 2004
- 6) Speaker: *Life Sciences FP6 European Research Proposals Meeting*, Poland 2005
- 7) Speaker: *P53 Marathon*, Ein Gedi, Israel, 2005
- 8) Speaker: *2nd IFOM –IEO Cancer Meeting*, Milan, Italy 2006
- 9) Speaker: *International p53 Workshop*, New York, USA 2006

- 10) Speaker: *P53 Marathon*, Frascati, Italy 2006
- 11) Speaker: *XIV Telethon Scientific Convention*, Salsomaggiore, Italy 2007
- 12) Speaker: *3rd International p73/p63 Workshop*, Rome, Italy 2007
- 13) Speaker: *World Stress Conference*, Budapest, Hungary 2007, August 25th. Title: "p53 family in apoptosis".
- 14) Speaker: *FEBS Workshop: The Biology of Modular Protein Domains*, Seefeld, Austria 2007, September 11th. Title: "The WW domain of YAP is critical in the execution of p73-mediated apoptosis in response to DNA damage"
- 15) Speaker: *Cancer Therapeutics: The Road Ahead*, Capri, Italy 2007, October 8th. Title: "Mutant p53 Gain of Function: SIMPs-mediated Disruption of the Protein Complex mutp53/p73 Enhances Selectively the Chemosensitivity of Mutant p53 Tumor Cells"
- 16) Speaker: *P53 Marathon. Deregulating the p53 Network : Origin and Consequences of TP53 mutations*, Lyon, France 2007, November 14th. Title: "Mutant p53: an oncogenic transcription factor"
- 17) Speaker: *Era of Hope Department of Defense Breast Cancer Research Program Meeting*, Baltimore, USA 2008, June.
- 18) Speaker. Title: "The Potential of Metformin Use in Breast Cancer", Turin, Italy, 2009
- 19) Speaker: *P53 Marathon*, Acre, Israel 2009, March 27th. Title: "Mutant p53 triggers an oncogenic autoregulatory feedback loop".
- 20) Speaker: University of Oxford, 2009, November 16th. Title: "Oncogenic cross-talks in human cancers".
- 21) Speaker:, 3rd International p63/73 Workshop, Rome, Italy, 2009, March 21st. Title: "Reactivation of p73 is dangerous for tumour cells".
- 22) Chair & Speaker: The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, Rome, Italy, 2009, April 22nd. Title: "YAP bridges p73 and PML pro-apoptotic pathways"
- 23) Chair & Speaker: The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, Rome, Italy, 2010, November 3rd. Title: "Role of YAP in apoptosis and senescence as tumour suppression mechanisms",
- 24) Speaker: Karolinska Institutet, Stockholm, 2010,. Title: "Oncogenic cross-talks in human cancers"
- 25) Speaker: SIBBM seminar: Frontiers in Molecular Biology, University of Padua, 2010, June 4th. Title: "Molecular determinants in breast cancer".

- 26) Speaker: University of Trieste, School of Molecular Biomedicine, 2011, March 30th. Title: "*Exploring tumour chemoresistance: miRNAs and cancer stem cells*".
- 27) Speaker: Institute San Raffaele in Milan, Department of Experimental Oncology, 2011. Title: "*Exploring tumor chemoresistance: miRNAs and cancer stem cells*"
- 28) Speaker: 5th Mutant p53 Workshop: "From bench to bedside across mouse models", Rome, Italy, 2011, May 23rd. Title: "*Oncogenic transcriptional activity of mutant p53*".
- 29) Chair: *Mutant p53 activities in vivo*: 5th Mutant p53 Workshop: "From bench to bedside across mouse models", Rome, Italy, 24th May, 2011.
- 28) Speaker: 53rd Annual Meeting of the Italian Cancer Society: "Back to the future", Translating cancer research from bedside to bench and back, Torino, Italy, 2011, October 22nd. Title: "*The Hippo-YAP pathway in organ size control tumorigenesis*".